[SCHEDULE 13G] Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock SEC Filing

Rhea-AI Filing Summary

Cyclacel Pharmaceuticals, Inc. Schedule 13G filed by Ong Yee Lung reports beneficial ownership of 218,000 shares of Cyclacel common stock, representing 9.8% of the class. The filer states sole voting and dispositive power over all 218,000 shares. The filing is submitted under Schedule 13G disclosures and includes a certification that the shares were not acquired to change or influence control of the issuer. Several items (group membership, holdings on behalf of others, and subsidiary/group identification) are marked Not Applicable.

Positive

• Material disclosure: Reporting of a >5% stake (218,000 shares, 9.8%) provides transparency to the market
• Sole voting and dispositive power: Filer explicitly reports exclusive control over voting and disposition of the shares
• Schedule 13G filing: Certification indicates the position is not held to influence or change control, consistent with passive investor reporting

Negative

• None.

Insights

Securities Analyst

TL;DR: A single investor reports a material ~9.8% stake with sole voting and dispositive power, filed on Schedule 13G indicating passive intent.

The filing discloses a material ownership stake (218,000 shares, 9.8%) by an individual, with exclusive voting and disposition rights. Filing on Schedule 13G and the certification language indicate the filer asserts the position is not intended to influence control, which typically signals passive ownership rather than an activist intent. There are no indications in the document of group affiliation, holdings for others, or transactions beyond the disclosed position.

Corporate Governance Expert

TL;DR: Disclosure meets regulatory requirements for a >5% passive holder, noting sole control of shares but no intent to change issuer control.

The statement identifies the reporting person as an individual citizen of Malaysia and provides residential and issuer office addresses. Key governance-related items—group identity, ownership on behalf of others, and subsidiary involvement—are explicitly marked Not Applicable. The certification asserts the shares were not acquired to influence control; absent other filings or agreements, this preserves customary passive-holder status under Schedule 13G.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Cyclacel Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

23254L876

(CUSIP Number)

07/28/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 23254L876

1

Names of Reporting Persons

Ong Yee Lung

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MALAYSIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 218,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 218,000.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

218,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.8 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Cyclacel Pharmaceuticals, Inc.
(b)	Address of issuer's principal executive offices: Level 10, Tower 11, Avenue 5, No. 8 Jalan Kerinchi, Kuala Lumpur, Malaysia
Item 2.
(a)	Name of person filing: Ong Yee Lung
(b)	Address or principal business office or, if none, residence: 9 JALAN LAWA 3 TAMAN PELANGI INDAH ULU TIRAM 81800 JOHOR MALAYSIA
(c)	Citizenship: Malaysia
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 23254L876
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 218,000
(b)	Percent of class: 9.8%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 218,000
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 218,000
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Ong Yee Lung

Signature:	/s/ Ong Yee Lung
Name/Title:	Ong Yee Lung
Date:	08/18/2025

Exhibit Information

sec.gov/Archives/edgar/data/1130166/000164117225015874/ex10-1.htm

FAQ

What stake does Ong Yee Lung report in Cyclacel (CYCCP)?

The filing reports 218,000 shares, representing 9.8% of the class.

Does the filer have voting control over the reported shares?

Yes. The filer reports sole voting power and sole dispositive power for all 218,000 shares.

Was the position disclosed as intended to influence control of Cyclacel?

No. The certification states the securities were not acquired to change or influence control and are reported on Schedule 13G.

Is the filer part of a group or holding shares for others?

No. The filing marks Not Applicable for group membership and for ownership on behalf of another person.

What is the filer’s citizenship and address information provided?

The filer is a citizen of Malaysia; a Malaysian residence address is provided in the filing.